Trial Profile
ALIMTA Plus Gemcitabine as Front-line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase II Clinical Trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2010
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Dec 2006 Status change
- 28 Jul 2006 Status change
- 07 Sep 2005 New trial record.